No Prescription |
 |
 | ||
|
RAZEL Crestor |
|
| ||
No Prescription » Prescription Drugs 14 » RAZEL Crestor Lipid lowering agent. (Primary hyper cholesterolaemia). Rosuvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body. It works by reducing levels of "badö cholesterol (low-density lipoprotein or LDL) and triglycerides in the blood while increasing levels of "goodö cholesterol. Rosuvastatin is a member of the statin class; the drugs of first choice for the treatment of dyslipidaemia. Multiple clinical studies have confirmed the effectiveness of Rosuvastatin in reducing LDL-C (æbadÆ cholesterol) and raising HDL-C (ægoodÆ cholesterol). Rosuvastatin is a statin indicated for the treatment of dyslipidaemia. Rosuvastatin is used with diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in your blood. Accumulation of cholesterol and fats along the walls of your arteries (a process known as atherosclerosis) decreases blood flow and therefore the oxygen supply to your heart brain and other parts of your body. Lowering your blood level of cholesterol and fats may help to prevent heart disease angina (chest pain) strokes and heart attacks. Buy RAZEL Crestor and other Prescription Drugs 14 products online at Medstore. Buy Online at Medstore - Click Here!
About RAZEL Crestor: Product Type: Prescription Drugs 14 RAZEL ( Crestor Generic Rosuvastatin ) RAZEL (Crestor Generic Rosuvastatin) Crestor Generic Rosuvastatin 20mg Crestor Generic Rosuvastatin RAZEL
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
